The FDA approved enlicitide (Lipfendra), a daily oral PCSK9 inhibitor developed by Merck, on July 16. Clinical data indicate it can reduce LDL cholesterol to 50-60 mg/dL. The drug carries a list price of $315 for a 30-day supply and is scheduled for availability within weeks.
“A new pill could help millions of people lower their cholesterol”
Read at CBS News →No right-leaning sources covered this
Approval expands access to aggressive LDL-lowering therapy via an oral option but the $315 monthly price continues to ration care along income lines.
“Need for Medicare negotiation and price caps to treat prevention as a public good”
Market-driven innovation delivers a convenient, lower-priced oral alternative that meets guideline targets without new government mandates.
“Private-sector R&D responding to demand for convenience and affordability”
The pill increases individual options and illustrates how competition can improve access, though FDA gatekeeping delayed market entry.
“Consumer sovereignty and reduced regulatory barriers”
All views rely on surrogate LDL endpoints and predecessor trial data rather than this drug's outcome studies, while overlooking adverse-effect signals and lifestyle alternatives.
“Over-reliance on class-effect extrapolation and guideline thresholds influenced by industry ties”
Ratings by MBFC